TNFRSF21 and amyotrophic lateral sclerosis: Moreover, our demonstration that targeting DR6 attenuates MN death opens a unique opportunity to test therapeutic strategies aimed at blocking/slowing nerve terminal degeneration, a combination of effects that is required to ultimately extend muscle function and thus greatly improve the quality of life for patients with ALS.